ranirestat, (AS-3201) — Competitive Intelligence Brief

ranirestat, (AS-3201) (ranirestat, (AS-3201)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aldose reductase inhibitor. Area: Endocrinology / Diabetes.

phase 3 Aldose reductase inhibitor Aldose reductase Endocrinology / Diabetes Small molecule

Target snapshot

ranirestat, (AS-3201) (ranirestat, (AS-3201)) — Sumitomo Pharma Co., Ltd.. Ranirestat inhibits aldose reductase, the first enzyme in the polyol pathway, to reduce sorbitol accumulation and prevent diabetic complications.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ranirestat, (AS-3201) TARGET	ranirestat, (AS-3201)	Sumitomo Pharma Co., Ltd.	phase 3	Aldose reductase inhibitor	Aldose reductase
Eabeth	EPALRESTAT		marketed	epalrestat	Aldose reductase	1992-01-01
Buphenyl	Buphenyl	Amgen	marketed		Aldose reductase, Histone deacetylase 1, Histone deacetylase 2
AO-128	AO-128	Takeda	marketed	Aldose reductase inhibitor	Aldose reductase
Pieceid	polydatin		marketed	pieceid	Glucose-6-phosphate 1-dehydrogenase, Aldose reductase
AT-007	AT-007	Applied Therapeutics, Inc.	phase 3	Aldose reductase inhibitor	Aldose reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aldose reductase inhibitor class)

1. Applied Therapeutics, Inc. · 1 drug in this class
2. Sumitomo Pharma Co., Ltd. · 1 drug in this class
3. Takeda · 1 drug in this class